ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions. The company's clinical-stage products include Miransertib (ARQ 092), an inhibitor of the AKT serine/threonine kinase in Phase 1/2 clinical trial in rare Overgrowth Diseases, Phase 1 clinical trial in the rare disease, and in Phase 1b in oncology in combination with the hormonal therapy and anastrozole; ARQ 751, a next-generation inhibitor of AKT that is in Phase I clinical trial for solid tumors harboring the AKT1 or PI3K mutation; ARQ 761, a ß-lapachone analog evaluated as a promoter of NQO1-mediated programmed cancer cell death which is in Phase 1/2 clinical trial in multiple oncology; and ARQ 531, an orally bioavailable, potent and reversible inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase 1 for B-cell malignancies refractory to other therapeutic options. It has collaboration agreement with Roivant Sciences Ltd. to develop derazantinib, a pan-FGFR inhibitor. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-994-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$4.71 million
Profitability
Miscellaneous
Employees32
OptionableOptionable
ArQule (NASDAQ:ARQL) Frequently Asked Questions
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) posted its quarterly earnings results on Wednesday, October, 31st. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01. The biotechnology company earned $4.98 million during the quarter, compared to the consensus estimate of $2.44 million. During the same period last year, the firm posted ($0.09) EPS. View ArQule's Earnings History.
When is ArQule's next earnings date?
What price target have analysts set for ARQL?
5 equities research analysts have issued 12 month price objectives for ArQule's stock. Their forecasts range from $7.00 to $7.00. On average, they expect ArQule's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 105.3% from the stock's current price. View Analyst Price Targets for ArQule.
What is the consensus analysts' recommendation for ArQule?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ArQule.
Has ArQule been receiving favorable news coverage?
News stories about ARQL stock have been trending negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. ArQule earned a news impact score of -2.8 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Prestige Consumer Healthcare (PBH), Allakos (ALLK), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), TherapeuticsMD (TXMD), Clovis Oncology (CLVS), Uniqure (QURE), Corcept Therapeutics (CORT), Cambrex (CBM), Spectrum Pharmaceuticals (SPPI), Phibro Animal Health (PAHC), Esperion Therapeutics (ESPR), Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE) and Vanda Pharmaceuticals (VNDA).
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Mr. Paolo Pucci, CEO & Director (Age 58)
- Mr. Peter S. Lawrence J.D., Pres, COO & Sec. (Age 56)
- Mr. Robert J. Weiskopf, CFO & Treasurer (Age 68)
- Dr. Brian Schwartz, Chief Medical Officer (Age 57)
- Ms. Dawn Schottlandt, VP of Investor Relations & Corp. Communications
Who are ArQule's major shareholders?
ArQule's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.91%), Millennium Management LLC (3.65%), Sphera Funds Management LTD. (1.86%), Northern Trust Corp (1.14%), Geode Capital Management LLC (1.09%) and Candriam Luxembourg S.C.A. (1.07%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.
Which institutional investors are selling ArQule stock?
ARQL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Opaleye Management Inc., Acadian Asset Management LLC, Bailard Inc., MetLife Investment Advisors LLC, Squarepoint Ops LLC, CAPROCK Group Inc. and Northern Trust Corp. View Insider Buying and Selling for ArQule.
Which institutional investors are buying ArQule stock?
ARQL stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Citigroup Inc., Two Sigma Investments LP, California Public Employees Retirement System, D. E. Shaw & Co. Inc., Chicago Equity Partners LLC, Dupont Capital Management Corp and Bank of New York Mellon Corp. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.
How do I buy shares of ArQule?
Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ARQL stock can currently be purchased for approximately $3.41.
How big of a company is ArQule?
ArQule has a market capitalization of $371.67 million and generates $4.71 million in revenue each year. The biotechnology company earns $-29,200,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. ArQule employs 32 workers across the globe.
What is ArQule's official website?
How can I contact ArQule?
ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]
MarketBeat Community Rating for ArQule (NASDAQ ARQL)
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
